$SKGR
SK Growth Opportunities Corp

2022 Q2 Form 10-Q Financial Statement

#000119312522218680 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $80.00K $40.00K
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $80.00K $40.00K
YoY Change
Operating Profit -$84.17K -$37.03K -$33.83K
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $7.289K $0.00 $0.00
YoY Change
Pretax Income -$80.00K -$40.00K
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$76.89K -$37.03K -$33.83K
YoY Change
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.300M $200.0K
YoY Change
Cash & Equivalents $2.266M $161.9K
Short-Term Investments
Other Short-Term Assets $0.00
YoY Change
Inventory
Prepaid Expenses $25.35K
Receivables
Other Receivables
Total Short-Term Assets $2.291M $200.0K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $205.0M
YoY Change
Other Assets $0.00 $400.0K
YoY Change
Total Long-Term Assets $205.0M $400.0K $31.99K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $2.291M $200.0K
Total Long-Term Assets $205.0M $400.0K $31.99K
Total Assets $207.3M $600.0K $31.99K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $659.9K $0.00
YoY Change
Accrued Expenses $201.9K $300.0K $40.82K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $300.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $861.8K $600.0K $40.82K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $5.000M $0.00
YoY Change
Other Long-Term Liabilities $7.000M
YoY Change
Total Long-Term Liabilities $12.02M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $861.8K $600.0K $40.82K
Total Long-Term Liabilities $12.02M $0.00
Total Liabilities $12.88M $600.0K $40.82K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$10.58M -$33.83K
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$10.58M -$45.86K -$8.831K
YoY Change
Total Liabilities & Shareholders Equity $207.3M $600.0K $31.99K
YoY Change

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$76.89K -$37.03K -$33.83K
YoY Change
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$60.00K -$38.36K $0.00
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$205.0M
YoY Change
Cash From Investing Activities -$205.0M $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 207.2M 200.3K 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -60.00K -38.36K 0.000
Cash From Investing Activities -205.0M 0.000
Cash From Financing Activities 207.2M 200.3K 0.000
Net Change In Cash 2.100M 161.9K 0.000
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$60.00K -$38.36K $0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001912461
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
SK Growth Opportunities Corporation
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
dei Entity File Number
EntityFileNumber
001-41432
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1643582
dei Entity Address Address Line1
EntityAddressAddressLine1
228 Park Avenue S #96693
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10003
dei City Area Code
CityAreaCode
917
dei Local Phone Number
LocalPhoneNumber
599-1622
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
true
CY2022Q2 us-gaap Cash
Cash
2265772
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
25350
CY2022Q2 us-gaap Assets Current
AssetsCurrent
2291122
CY2021Q4 skgr Deferred Offering Costs Non Current
DeferredOfferingCostsNonCurrent
31985
CY2022Q2 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
205007289
CY2022Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
205007289
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
31985
CY2022Q2 us-gaap Assets
Assets
207298411
CY2021Q4 us-gaap Assets
Assets
31985
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
659915
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
201934
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
40816
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
861849
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40816
CY2022Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
20794
CY2022Q2 skgr Overfunding Loan
OverfundingLoan
5000000
CY2022Q2 skgr Deferred Underwriting Commissions And Advisory Fees
DeferredUnderwritingCommissionsAndAdvisoryFees
7000000
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
12020794
CY2022Q2 us-gaap Liabilities
Liabilities
12882643
CY2021Q4 us-gaap Liabilities
Liabilities
40816
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
990000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
990000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24425
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10584807
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33831
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-10584232
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-8831
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
207298411
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31985
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
84174
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
121206
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-84174
us-gaap Operating Income Loss
OperatingIncomeLoss
-121206
CY2022Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
7289
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
7289
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7289
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7289
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-76885
us-gaap Net Income Loss
NetIncomeLoss
-113917
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-8831
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-37032
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-45863
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
6600000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
3000000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
191121
CY2022Q2 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
19870363
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-76885
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-10584232
us-gaap Net Income Loss
NetIncomeLoss
-113917
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
7289
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
25350
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
31212
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
18103
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-97241
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
205000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-205000000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
300000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
300000
skgr Reimbursement From Underwriter
ReimbursementFromUnderwriter
400000
skgr Proceeds Received From Overfunding Loan
ProceedsReceivedFromOverfundingLoan
5000000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
200000000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
6600000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4636987
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
207363013
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2265772
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2265772
skgr Offering Costs Included In Accounts Payable
OfferingCostsIncludedInAccountsPayable
628703
skgr Offering Costs Included In Accrued Offering Costs
OfferingCostsIncludedInAccruedOfferingCosts
175000
CY2022Q2 skgr Deferred Underwriting Commissions And Advisory Fees
DeferredUnderwritingCommissionsAndAdvisoryFees
7000000
skgr Reversal Of Previous Accrued Offering Costs
ReversalOfPreviousAccruedOfferingCosts
31985
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2021-12-08
CY2022Q2 skgr Total Offering Costs In Connection Within Initial Public Offering
TotalOfferingCostsInConnectionWithinInitialPublicOffering
12000000
CY2022Q2 skgr Deferredunderwritingcommissions
Deferredunderwritingcommissions
7000000
CY2022Q2 skgr Number Of Days Granted To Underwriters To Subscribe Shares Pursuant To Overallotment Option
NumberOfDaysGrantedToUnderwritersToSubscribeSharesPursuantToOverallotmentOption
P45D
CY2022Q2 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
205000000
CY2022Q2 skgr Per Share Value Of Restricted Asset
PerShareValueOfRestrictedAsset
10.25
skgr Businesscombinationconsummateperiodlimit
Businesscombinationconsummateperiodlimit
P180D
CY2022Q2 skgr Percentage Of Public Shares That Can Be Transferred Without Any Restriction
PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction
0.15
skgr Percentage Of Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
skgr Period Within Which Business Combination Shall Be Consummated From The Consummation Of Initial Public Offer
PeriodWithinWhichBusinessCombinationShallBeConsummatedFromTheConsummationOfInitialPublicOffer
P18M
skgr Period Within Which Business Combination Shall Be Consummated From The Consummation Of Initial Public Offer If A Definitive Agreement Executed Relating To Business Combination
PeriodWithinWhichBusinessCombinationShallBeConsummatedFromTheConsummationOfInitialPublicOfferIfADefinitiveAgreementExecutedRelatingToBusinessCombination
P21M
CY2022Q2 us-gaap Liquidation Basis Of Accounting Accrued Costs To Dispose Of Assets And Liabilities
LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities
100000
CY2022Q2 us-gaap Share Price
SharePrice
10.25
CY2022Q2 us-gaap Share Price
SharePrice
10.25
CY2022Q2 us-gaap Cash
Cash
2300000
CY2022Q2 skgr Working Capital
WorkingCapital
1400000
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.5
CY2022Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the unaudited condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit o</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">f $250,000. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June 30, 2022 and December 31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. </div></div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div>
CY2022Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
skgr Additional Time Frame For Completion Of Business Combination
AdditionalTimeFrameForCompletionOfBusinessCombination
three months each time for a total of up to 24 months
CY2022Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
skgr Restricted Investments Term
RestrictedInvestmentsTerm
P180D
CY2021Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
one-to-one
CY2022Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
skgr Underwriting Discount Paid Per Unit
UnderwritingDiscountPaidPerUnit
0.2
us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
4000000
skgr Deferred Underwriting Commission Per Unit
DeferredUnderwritingCommissionPerUnit
0.35
CY2022Q2 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
7000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
990000
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
990000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2022Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
skgr Percentage Of Over Allotment Option Amount Would Be Exercised
PercentageOfOverAllotmentOptionAmountWouldBeExercised
0.25

Files In Submission

Name View Source Status
0001193125-22-218680-index-headers.html Edgar Link pending
0001193125-22-218680-index.html Edgar Link pending
0001193125-22-218680.txt Edgar Link pending
0001193125-22-218680-xbrl.zip Edgar Link pending
d371511d10q.htm Edgar Link pending
d371511dex311.htm Edgar Link pending
d371511dex312.htm Edgar Link pending
d371511dex321.htm Edgar Link pending
d371511dex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
skgr-20220630.xsd Edgar Link pending
skgr-20220630_cal.xml Edgar Link unprocessable
skgr-20220630_def.xml Edgar Link unprocessable
skgr-20220630_lab.xml Edgar Link unprocessable
d371511d10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
skgr-20220630_pre.xml Edgar Link unprocessable